Fundz

Imbria Pharmaceuticals reported raising $59.2 Million in an initial SEC Form D filing, from an offering of $124 Million

PRIVATEApr 01, 2025$59.2M of $124.2M raised

Amount Raised

$59.2 Million

$59.2 Million per company press release (Apr 10, 2025)

Round Type

Venture

BostonBiotechnologyHealth Care

Investors

SV Health InvestorsRA Capital ManagementCytokinetics, Inc.Catalio Capital ManagementAN VenturesDeep Track Capital

Quick answer

Imbria Pharmaceuticals raised $59.2 Million in a funding round, dated March 10, 2025. Investors: SV Health Investors, RA Capital Management, Cytokinetics, Inc., Catalio Capital Management, AN Ventures and Deep Track Capital. Imbria Pharmaceuticals is based in Boston, Massachusetts, United States.

How much did Imbria Pharmaceuticals raise?
Imbria Pharmaceuticals raised $59.2 Million in a funding round on March 10, 2025.
Who invested in Imbria Pharmaceuticals?
SV Health Investors, RA Capital Management, Cytokinetics, Inc., Catalio Capital Management, AN Ventures and Deep Track Capital are named as investors in this round.
What does Imbria Pharmaceuticals do?
Imbria is a privately held, clinical stage company developing novel therapies for patients with life-altering cardiometabolic disorders.
Where is Imbria Pharmaceuticals based and how big is it?
Imbria Pharmaceuticals is based in Boston, Massachusetts, United States.
Who are the decision-makers at Imbria Pharmaceuticals?
Fundz holds 1 contact at Imbria Pharmaceuticals. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as Imbria Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.

  • Coologics raised $3M (Seed) on April 23, 2025.
  • Conavi Medical raised $16M on April 23, 2025.
  • Biolinq raised $100M (Series C) on April 22, 2025.
  • Retension Pharmaceuticals raised $12M on April 22, 2025.
  • CERo Therapeutics Holdings raised $5M on April 22, 2025.
  • HepaRegeniX GmbH raised $25M (Funding Round) on April 21, 2025.

Who to call at Imbria Pharmaceuticals, and when

A new round usually means Imbria Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Imbria Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Imbria Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Imbria Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Imbria Pharmaceuticals

Location

265 Franklin Street

Boston, Massachusetts, United States

About

Imbria is a privately held, clinical stage company developing novel therapies for patients with life-altering cardiometabolic disorders. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits. The lead product candidate, ninerafaxstat, is currently in Phase 2 clinical development in three indications: nHCM, stable angina, and HFpEF.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Imbria Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Imbria Pharmaceuticals's next move

See what Strategic adds

Imbria Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.